41957-64-6

Usage

Uses

Used in Pharmaceutical Industry:
3-Methoxy-2-phenylquinoline-4-carboxylic acid is used as a chemical intermediate for the synthesis of various pharmaceuticals due to its potential biological activity. It is particularly valued for its antimicrobial and antifungal properties, making it a candidate for the development of new treatments for infectious diseases.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Methoxy-2-phenylquinoline-4-carboxylic acid is used as a precursor in the production of agrochemicals. Its antimicrobial and antifungal properties are harnessed to develop compounds that protect crops from diseases and pests, thereby enhancing agricultural productivity.
Used in Anticancer Research:
3-Methoxy-2-phenylquinoline-4-carboxylic acid is used as a subject of research for its potential anti-inflammatory and anticancer properties. Studies are conducted to explore its ability to target and treat cancer cells, potentially leading to the development of novel therapeutic agents for cancer treatment.
Used in Disease Treatment:
3-METHOXY-2-PHENYLQUINOLINE-4-CARBOXYLIC ACID is also being investigated for its potential use in the treatment of various diseases beyond cancer and infectious diseases, given its demonstrated biological activity, which could have broad implications for human and animal health.

Upstream product

• 4079-52-1 methoxymethyl phenyl ketone 
• 91-56-5 indole-2,3-dione 

Downstream Products

• 174636-95-4 3-methyloxy-2-phenyl-4-quinolinecarbonyl chloride 
• 746637-39-8 3-methyloxy-N',2-diphenyl-4-quinolinecarbohydrazide 
• 298689-35-7 N-(2-Amino-2-phenylbutyl)-3-methoxy-2-phenylquinoline-4-carboxamide 
• 298689-29-9 2-(3-Methoxy-2-phenylquinolin-4-yl)-5-phenyl-5-propyl-2-oxazoline 
• 191796-72-2 (S)-N-(α-ethylbenzyl)-3-(ethoxycarbonylmethoxy)-2-phenylquinoline-4-carboxamide 
• 174636-33-0 (S)-(-)-N-(α-ethylbenzyl)-3-hydroxy-2-phenyl-4-quinoline carboxamide 
• 174636-26-1 (+/-)-Talnetant 
• 174636-32-9 talnetant 
• 485-89-2 oxycinchophen 

Relevant academic research and scientific papers

Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3- hydroxy-2-phenylquinoline-4-carboxamide (SB 223412)

Optimization of the previously reported 2-phenyl-4-quinolinecarboxamide NK-3 receptor antagonist 14, with regard to potential metabolic instability of the ester moiety and affinity and selectivity for the human neurokinin-3 (hNK-3) receptor, is described. The ester functionality could be successfully replaced by the ketone (31) or by lower alkyl groups (Et, 21, or n-Pr, 24). Investigation of the substitution pattern of the quinoline ring resulted in the identification of position 3 as a key position to enhance hNK-3 binding affinity and selectivity for the hNK-3 versus the hNK-2 receptor. All of the chemical groups introduced at this position, with the exception of halogens, increased the hNK-3 binding affinity, and compounds 53 (3-OH, SB 223412, hNK- 3-CHO binding K(i) = 1.4 nM) and 55 (3-NH2, hNK-3-CHO binding K(i) = 1.2 nM) were the most potent compounds of this series. Selectivity studies versus the other neurokinin receptors (hNK-2-CHO and hNK-1-CHO) revealed that 53 is about 100-fold selective for the hNK-3 versus hNK-2 receptor, with no affinity for the hNK-1 at concentrations up to 100 μM. In vitro studies demonstrated that 53 is a potent functional antagonist of the hNK-3 receptor (reversal of senktide-induced contractions in rabbit isolated iris sphincter muscles and reversal of NKB-induced Ca2+ mobilization in CHO cells stably expressing the hNK-3 receptor), while in vive this compound showed oral and intravenous activity in NK-3 receptor-driven models (senktide-induced behavioral responses in mice and senktide-induced miosis in rabbits). Overall, the biological data indicate that (S)-N-(1-phenylpropyl)-3-hydroxy- 2-phenylquinoline-4-carboxamide (53, SB 223412) may serve as a pharmacological tool in animal models of disease to assess the functional and pathophysiological role of the NK-3 receptor and to establish therapeutic indications for non-peptide NK-3 receptor antagonists.